Versartis, Inc. Completes Series A Funding of $11 Million [€7.9 M] in a Joint Venture between Index Ventures and Amunix, Inc. Redwood City, CA – June 2, 2009 – Versartis, Inc. announced today that it has closed a Series A financing with an initial commitment of $11 million [€7.9 M] from Index
SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes AMSTERDAM, August 17 - SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel
XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics Redwood City and Mountain View, CA – November 15, 2009 – Amunix, Inc. and Versartis, Inc. announced today that the scientific journal Nature Biotechnology